Based on the key indicators related to Adverum Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Adverum Biotechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Adverum Biotechnologies' Liabilities And Stockholders Equity is very stable compared to the past year. As of the 6th of January 2026, Non Current Liabilities Total is likely to grow to about 104.1 M, while Total Current Liabilities is likely to drop about 15.4 M. Key indicators impacting Adverum Biotechnologies' financial strength include:
Investors should never underestimate Adverum Biotechnologies' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Adverum Biotechnologies' cash flow, debt, and profitability to make informed and accurate decisions about investing in Adverum Biotechnologies.
Understanding current and past Adverum Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adverum Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Adverum Biotechnologies' assets may result in an increase in income on the income statement.
Adverum Biotechnologies competes with Artiva Biotherapeutics, Fractyl Health, Sutro Biopharma, Precision BioSciences, and Metagenomi Common. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Adverum Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adverum Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adverum Biotechnologies competition to find correlations between indicators driving Adverum Biotechnologies's intrinsic value. More Info.
Adverum Biotechnologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Adverum Biotechnologies' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adverum Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Adverum Biotechnologies Market Pulse
Quote
4.36
Change(%)
0.00
Change
0.00
Open
4.36
Low
4.36
High
4.36
Volume
0
Exchange
NASDAQ
Today, most investors in Adverum Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adverum Biotechnologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adverum Biotechnologies growth as a starting point in their analysis.
Adverum Biotechnologies January 6, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adverum Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adverum Biotechnologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adverum Biotechnologies based on widely used predictive technical indicators. In general, we focus on analyzing Adverum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adverum Biotechnologies's daily price indicators and compare them against related drivers.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.57)
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.77)
Return On Equity
(4.18)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.